Experimental and Clinical Pharmacology: COX-2 inhibitors

Pharmacology, Clinical and Experimental

This book, written by Meyer and Gottlieb, professors of pharmacology at Vienna and Heidelberg, respectively, has been translated into English by Halsey, professor of pharmacology and clinical medicine at Tulane. It deals with " scientific drug therapy" and confines itself to that portion of pharmacology which should aid the physician in practising his profession. Medicinal substances are dealt ...

COX-2 inhibitors.

Cyclooxygenase-2 (COX-2) inhibitors constitute a new group of non-steroidal anti-inflammatory drugs (NSAIDs) which, at recommended doses, block prostaglandin production by cyclooxygenase-2, but not by cyclooxygenase-1. Two COX-2 inhibitors are currently available in Australia--celecoxib, which is taken twice daily, and rofecoxib, which is taken once daily. Both drugs act rapidly in providing pa...

The Role of COX-2 Inhibitors on Experimental Colitis

The cardiovascular pharmacology of COX-2 inhibition.

Selective inhibitors of cyclooxygenase (COX)-2, the coxibs, were developed to inhibit inflammatory prostaglandins derived from COX-2, while sparing gastroprotective prostaglandins primarily formed by COX-1. However, COX-2-derived prostaglandins mediate not only pain and inflammation but also affect vascular function, the regulation of hemostasis/ thrombosis, and blood pressure control. All coxi...

Selective COX-2 Inhibitors: Towards Defining Their Appropriate Clinical Role

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used therapeutic agents. With the introduction of the selective cyclooxygenase-2 (COX-2) inhibitors, the use of this category of medications has expanded; however, the appropriate place for these agents in the therapeutic armamentarium is yet to be defined. Selective COX-2 inhibitors are effective in treating both acute a...